Study on the metabolic fate of catena-(S)-[mu-[N alpha-(3- aminopropionyl)histidinato(2-)-N1,N2,O:N tau]-zinc]. 1st communication: absorption, distribution, metabolism and excretion after single administration to rats
- PMID: 1796927
Study on the metabolic fate of catena-(S)-[mu-[N alpha-(3- aminopropionyl)histidinato(2-)-N1,N2,O:N tau]-zinc]. 1st communication: absorption, distribution, metabolism and excretion after single administration to rats
Abstract
Studies on the absorption, distribution, metabolism and excretion of 14C-Z-103 and 65Zn-Z-103 (catena-(S)-[mu-[N alpha-(3- aminopropionyl)histidinato(2-)-N1,N2,O:N tau]-zinc], CAS 107667-60-7) were performed after oral administration to rats. After oral administration of 14C-Z-103 and 65Zn-Z-103, the blood concentrations of 14C-radioactivity were 30- to 40-fold higher than those of 65Zn-radioactivity. The 14C-radioactivity showed a dose-dependent increase of Cmax and AUC values in the dose range from 13.1 mg/kg to 100 mg/kg, and remained longer in the blood. In contrast, no dose-dependent increase of AUC was observed with 65Zn-radioactivity, suggesting saturation of absorption at doses more than 30 mg/kg of 65Zn-Z-103. The major route of excretion of 14C-radioactivity was by excretion into the expired air, amounting to 38.8% of the administered dose, while the urinary and fecal excretions were low values at 4.1% and 13.3%, respectively. The radioactivity remaining in the carcass accounted for 39.3% of the dose. On the other hand, in the case of 65Zn-radioactivity, 85.0% of the administered dose was excreted into the feces and 10.5% of the dose remained in the carcass. Both 14C- and 65Zn-radioactivities were distributed to the whole body, while 14C-radioactivity showed higher concentrations in the body, and was retained longer than the 65Zn-radioactivity. When the plasma and the liver and kidney homogenates, from rats received 14C-Z-103, were treated with trichloroacetic acid (TCA), the radioactivities in the TCA-insoluble fraction increased as a function of time. Following the treatment of the homogenates with protease, the radioactivities in the TCA-insoluble fraction decreased. In vitro study was showed that L-carnosine of 14C-Z-103 added to the homogenates of liver and small intestine was metabolized to L-histidine. The results suggest that the remaining radioactivities in tissues and organs caused the incorporation of the metabolites of 14C-Z-103 into endogenous high molecular substances.
Similar articles
-
Study on the metabolic fate of catena-(S)-[mu-[N alpha-(3- aminopropionyl)histidinato(2-)-N1,N2,O:N tau]-zinc]. 2nd communication: absorption, distribution, metabolism and excretion after repeated administration to rats.Arzneimittelforschung. 1991 Sep;41(9):976-83. Arzneimittelforschung. 1991. PMID: 1796928
-
Study on the metabolic fate of catena-(S)-[mu-N alpha-(3-aminopropionyl)histidinato(2-)-N1,N2,O:N tau]-zinc]. 3rd communication: transfer into fetus and milk in rats.Arzneimittelforschung. 1991 Sep;41(9):984-91. Arzneimittelforschung. 1991. PMID: 1796929
-
Study on the metabolic fate of catena-(S)-[mu-[N alpha-(3-aminopropionyl)histidinato(2-)-N1,N2,O:N tau]-zinc]. 4th communication: disposition of zinc and amino acids in rats, dogs and monkeys.Arzneimittelforschung. 1991 Sep;41(9):992-5. Arzneimittelforschung. 1991. PMID: 1796930
-
Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review.Arzneimittelforschung. 2001 Sep;51(9):699-725. doi: 10.1055/s-0031-1300105. Arzneimittelforschung. 2001. PMID: 11642003 Review.
-
Recent advances on polaprezinc for medical use (Review).Exp Ther Med. 2021 Dec;22(6):1445. doi: 10.3892/etm.2021.10880. Epub 2021 Oct 14. Exp Ther Med. 2021. PMID: 34721687 Free PMC article. Review.
Cited by
-
Drug repositioning of polaprezinc for bone fracture healing.Commun Biol. 2022 May 16;5(1):462. doi: 10.1038/s42003-022-03424-7. Commun Biol. 2022. PMID: 35577977 Free PMC article.
-
Safety of zinc l-carnosine as a Novel food pursuant to Regulation (EU) 2015/2283 and the bioavailability of zinc from this source in the context of Directive 2002/46/EC on food supplements.EFSA J. 2022 Jun 10;20(6):e07332. doi: 10.2903/j.efsa.2022.7332. eCollection 2022 Jun. EFSA J. 2022. PMID: 35706682 Free PMC article.
-
Blood cell, liver function, and response changes by PEG-interferon-alpha2b plus ribavirin with polaprezinc therapy in patients with chronic hepatitis C.Hepatol Int. 2008 Mar;2(1):111-5. doi: 10.1007/s12072-007-9029-y. Epub 2008 Jan 11. Hepatol Int. 2008. PMID: 19669286 Free PMC article.
-
Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.World J Gastroenterol. 2006 Feb 28;12(8):1265-9. doi: 10.3748/wjg.v12.i8.1265. World J Gastroenterol. 2006. PMID: 16534882 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Research Materials